Extrait

1. Compare the Progression Free Survival (PFS) as assessed by CAC blinded central review according to the International Myeloma Working Group response criteria, (IMWG criteria) between treatment arms. 2. Compare the Overall Survival (OS) between Treatment arms.

Critère d'inclusion

• Patients with refractory or relapsed and refractory multiple myeloma (rrMM) who have failed at least 2 lines of prior treatment and have been previously exposed to an immunomodulatory drug (IMiDs) as lenalidomide or thalidomide and a proteasome inhibitor as bortezomib or carfilzomib

Liens

• ictrp
• ictrp
• euctr
• euctr
• euctr